Health-related quality of life ( HRQoL ) was an exploratory endpoint in the PALETTE trial , a global , double-blind , randomized , phase 3 trial of pazopanib 800 mg versus placebo as second-line or later treatment for patients with advanced soft tissue sarcoma ( N = 369 ) .